5-(5-bromo-2-hydroxy-benzylidene)-2-thioxo-thiazolidin-4-one | 6318-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 5-(5-bromo-2-hydroxy-benzylidene)-2-thioxo-thiazolidin-4-one
• 英文别名: 5-(5-Brom-2-hydroxy-benzyliden)-2-thioxo-thiazolidin-4-on；(5Z)-5-[(5-bromo-2-hydroxyphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
• CAS: 6318-35-0
• 化学式: C₁₀H₆BrNO₂S₂
• 分子量: 316.199
• InChiKey: ARKQCBSGSQCIEZ-YWEYNIOJSA-N

物化性质

• 熔点：
  233 °C (decomp)
• 密度：
  1.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  罗丹宁 、 5-溴水杨醛 在 ammonium acetate 、 溶剂黄146 作用下， 以 苯 为溶剂， 生成 5-(5-bromo-2-hydroxy-benzylidene)-2-thioxo-thiazolidin-4-one
  参考文献：
  名称：

  Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors

  摘要：

  A series of rhodanine derivatives was synthesized and evaluated for their ability to inhibit PRL-3. Benzylidene rhodanine derivative showed good biological activity, while compound 5e was the most active in this series exhibiting IC50 value of 0.9 mu M in vitro and showed a reduced invasion in cell-based assay. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.060

文献信息

• [EN] RHODANDSE DERIVARIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME<br/>[FR] DÉRIVÉS DE RHODAMINE, LEUR PROCÉDÉ DE PRÉPARATION ET SUR PRÉPARATIONS PHARMACEUTIQUES LES CONTENANT.
  申请人：KOREA RES INST OF BIOSCIENCE

  公开号：WO2007081091A1

  公开（公告）日：2007-07-19

  [EN] Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTPlB, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PPl and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity fliereof is modulated.
  [FR] L'invention porte sur des dérivés de rhodamine, sur leur procédé de préparation et sur des préparations pharmaceutiques les contenant.Lesdits dérivés présentent une activité inhibitrice contre les phosphatases protéiques (PPases) telles que PTPlB, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PPl et VHR, et peuvent servir et à prévenir les maladies dues aux PPases dont: les maladies autoimmunes, le diabète, la diminution de la tolérance au glucose, la résistance à l'insuline, l'obésité, les cancers, etc. lorsque leur activité inhibitrice est modulée.
• Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors
  作者：Jin Hee Ahn、Seung Jun Kim、Woul Seong Park、Sung Yun Cho、Jae Du Ha、Sung Soo Kim、Seung Kyu Kang、Dae Gwin Jeong、Suk-Kyeong Jung、Sang-Hyeup Lee、Hwan Mook Kim、Song Kyu Park、Ki Ho Lee、Chang Woo Lee、Seong Eon Ryu、Joong-Kwon Choi

  DOI：10.1016/j.bmcl.2006.02.060

  日期：2006.6

  A series of rhodanine derivatives was synthesized and evaluated for their ability to inhibit PRL-3. Benzylidene rhodanine derivative showed good biological activity, while compound 5e was the most active in this series exhibiting IC50 value of 0.9 mu M in vitro and showed a reduced invasion in cell-based assay. (c) 2006 Elsevier Ltd. All rights reserved.